Terra Innovatum and GSR III Acquisition Corp. Remind Shareholders to Vote and Approve the Business Combination Prior to the October 7 Extraordinary General Meeting of Shareholders

Core Viewpoint - Terra Innovatum Srl is advancing its micro-modular nuclear reactor technology and is in the process of merging with GSR III Acquisition Corp, with a shareholder vote scheduled for October 7, 2025, to approve the business combination [1][4]. Company Overview - Terra Innovatum is focused on developing the SOLO™ micro-modular nuclear reactor, targeting commercialization by 2028, and has made significant progress by securing a deployment site and partnerships for component and fuel manufacturing [5][10]. - The company aims to provide scalable, safe, and environmentally friendly nuclear power solutions, addressing global energy shortages with innovative technology [10][11]. Business Combination Details - GSR III Acquisition Corp will hold an extraordinary general meeting on October 7, 2025, to vote on the proposed business combination with Terra Innovatum [2][6]. - If approved, the combined entity will operate under the name Terra Innovatum and its shares are expected to trade on Nasdaq under the ticker symbol "NKLR" [4]. Technology and Product Features - The SOLO™ reactor utilizes proliferation-resistant low-enriched uranium (LEU) fuel, ensuring safety and global deployment without reliance on experimental fuels [7]. - The reactor is designed with inherent safety features to prevent meltdowns and hydrogen explosions, and it can be manufactured in a factory setting for efficient deployment [7][12]. - SOLO™ is compact, requiring minimal space, and can be deployed in various settings, including industrial hubs and remote areas, with flexible grid integration options [7][12]. Market Applications - SOLO™ is positioned to provide CO2-free power solutions for diverse applications, including data centers, remote towns, and large-scale industrial operations in sectors like cement, oil and gas, and steel manufacturing [12]. - The reactor also has the capability to produce medical radioisotopes, contributing to oncology research and cancer treatment [12].